We hear that as at April 2007 you planned to survive Daiichi Asubio Pharma as an independent entity. Why?
A2. The strengths of Daiichi Asubio Pharma are in biotechnology-based drugs and peptide research, and we wish to work on drug discovery by taking advantage of these features. Concerning company structure, we wish not to stay independent going forward, instead we will devise development fields and drug discovery fields within our interim-term management plan that would generate the most synergy for Daiichi Sankyo Group.
Related Questions
- If an entity is acquired by, or merges with, a NASDAQ-listed company, may a former officer of the acquired entity be eligible to qualify as an independent director of the combined entity?
- We hear that as at April 2007 you planned to survive Daiichi Asubio Pharma as an independent entity. Why?
- Can a business entity enroll as an Independent Trader?
